Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection
Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM,
Efficacy of Ebola Glycoprotein-Specific Equine Polyclonal Antibody Product Against Lethal Ebola Virus Infection in Guinea Pigs
Chan M, Holtsberg FW, Vu H, Howell KA, Leung A,
Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms
Warfield KL, Howell KA, Vu H, Geisbert J, Wong G,
Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins
Nyakatura EK, Zak SE, Wec AZ, Hofmann D, Shulenin S,
Structural basis of broad ebolavirus neutralization by a human survivor antibody
West BR, Wec AZ, Moyer CL, Fusco ML, Ilinykh PA,
Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability
Zhao X, Howell KA, He S, Brannan JM, Wec AZ, Davidson E,
Protective efficacy of a novel alpha hemolysin subunit vaccine (AT62) against Staphylococcus aureus skin and soft tissue infections.
Adhikari RP, Thompson CD, Aman MJ, Lee JC. Vaccine. 2016 Dec
Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus.
Howell KA, Brannan JM, Bryan C, McNeal A, Davidson E, Turner
Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVax.
Chen WH, Pasetti MF, Adhikari RP, Baughman H, Douglas R,
A “Trojan Horse” Bispecific Antibody Strategy for Broad Protection against Ebolaviruses.
Wec, A.Z. Nyakatura, E.K. Herbert, A.S. Howell, K.A. Holtsberg, F.W.
